ATG9B

Across TCGA pan-cancer cohorts, ATG9B Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ATG9B data layer compared with 25 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher ATG9B Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated ATG9B expression acts as an unfavorable survival marker.

LUSC, STAD, and UCEC are the cancer types where ATG9B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	DFS	Median	II,III,IV	0.189	0.719	<.001	27	view →
STAD	OS	Median	II,III,IV	0.163	0.663	<.001	21	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
COAD	OS	Median	III,IV	0.159	0.692	.021	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ATG9B–LUSC (DFS)

Open the LUSC breakdown →